We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Imago BioSciences Inc | NASDAQ:IMGO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 36.01 | 37.82 | 34.21 | 0 | 00:00:00 |
As filed with the Securities and Exchange Commission on January 11, 2023
Registration No. 333-258057
Registration No. 333-263828
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
IMAGO BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 45-4915810 | |
(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification Number) |
2012 Equity Incentive Plan
2021 Incentive Award Plan
2021 Employee Stock Purchase Plan
(Full title of the plan)
Kelly E.W. Grez, Secretary
Imago BioSciences, Inc.
303 Twin Dolphin Drive, 6th Floor
Redwood City, California 94065
(415) 529-5055
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Saee Muzumdar
Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, NY 10166-0193
(212) 351-4035
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
TERMINATION OF REGISTRATION
This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (each, a Registration Statement and collectively, the Registration Statements) filed by Imago BioSciences, Inc. (the Company) with the Securities and Exchange Commission:
| Registration No. 333-258057, filed on July 21, 2021, registering 3,171,061 shares of common stock under the Companys 2012 Equity Incentive Plan, 3,450,000 shares of common stock under the Companys 2021 Incentive Award Plan, and 350,000 shares of common stock under the Companys 2021 Employee Stock Purchase Plan. |
| Registration No. 333-263828, filed on March 24, 2022, registering 1,676,587 shares of common stock under the Companys 2021 Incentive Award Plan, and 335,317 shares of common stock under the Companys 2021 Employee Stock Purchase Plan. |
Pursuant to the Agreement and Plan of Merger, dated as of November 19, 2022 (the Merger Agreement), by and among the Company, Merck Sharp & Dohme LLC, a New Jersey limited liability company (Parent) and M-Inspire Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Company has terminated all offerings of its securities pursuant to the Registration Statements and hereby removes and withdraws from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.
1
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rahway, in the State of New Jersey, on this 11th day of January, 2023.
IMAGO BIOSCIENCES, INC. (REGISTRANT) | ||
By: | /s/ Kelly E.W. Grez | |
Name: | Kelly E.W. Grez | |
Title: | Secretary |
Pursuant to the Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment to Registration Statements.
2
1 Year Imago BioSciences Chart |
1 Month Imago BioSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions